Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity

Molecules. 2021 Sep 15;26(18):5601. doi: 10.3390/molecules26185601.


Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

Keywords: anti-inflammatory; cannabigerol; cannabinoid; obesity.

MeSH terms

  • Analgesics / chemical synthesis*
  • Analgesics / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / chemical synthesis*
  • Anti-Inflammatory Agents / therapeutic use
  • Anti-Obesity Agents / chemical synthesis*
  • Anti-Obesity Agents / therapeutic use
  • Cannabinoids / chemistry*
  • Fatty Liver / drug therapy
  • Female
  • Mice
  • Mice, Inbred C57BL
  • Obesity / drug therapy
  • Osteoarthritis, Knee / drug therapy


  • Analgesics
  • Anti-Inflammatory Agents
  • Anti-Obesity Agents
  • Cannabinoids
  • cannabigerol